Overview

* Arvinas ( ARVN ) Q3 revenue drops significantly year-over-year, impacted by completed Novartis agreements

* Net loss for Q3 narrows compared to last year

* R&D expenses decrease due to lower external and personnel costs

Outlook

* Arvinas ( ARVN ) plans to initiate a Phase 1b trial for ARV-102 in PSP patients in 1H 2026

* Company expects to present ARV-393 data at a medical congress in 2026

* Arvinas ( ARVN ) plans to continue ARV-806 Phase 1 trial enrollment in KRAS G12D tumors

Result Drivers

* R&D EXPENSES - The decrease in R&D expenses of $22.2 million for the quarter was primarily due to a decrease in external expenses of $7.4 million and a decrease in compensation and related personnel expenses of $14.2 million

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $41.90

Revenue mln

Q3 Net -$35.10

Income mln

Q3 $85.70

Operatin mln

g

Expenses

Q3 -$43.80

Operatin mln

g income

Q3 -$34.80

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Arvinas Inc ( ARVN ) is $13.00, about 26.6% above its November 4 closing price of $9.54

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)